All posts related to "pharmacare"

JointHealth™ Survey on BC PharmaCare policy

Check

JointHealth™ Survey on BC PharmaCare policy

Arthritis Consumer Experts (ACE) is asking for your valuable feedback on new BC PharmaCare policy.

Arthritis Consumer Experts (ACE) is asking for your valuable feedback on new BC PharmaCare policy. Gathering your views is very important to the advocacy work that we do on your behalf.

This survey includes 13 questions for people living with arthritis and will take approximately 10 minutes to complete. Your participation will be anonymous and the results will be pooled for analysis to assure your complete privacy. Your responses will in no way impact on your health care or public health insurance coverage.

Thank you for taking the time to participate in this important survey. Your feedback helps us to improve the quality and relevance of Arthritis Consumer Experts’ work.

If you have any questions or comments, please contact us at: feedback@jointhealth.org.

Better Pharmacare Coalition poll reveals British Columbians…

BC Map Cutout…oppose changes to planned expansion to BC government’s Reference Drug Plan. Better Pharmacare Coalition eager to work with government to get it right for patients

A recent Better Pharmacare Coalition (BPC) poll has found that British Columbians oppose expansion of the Ministry of Health’s Reference Drug Program based on concerns that expansion could compromise patient health.

The BC government has approved amendments to the Drug Price Regulation that will expand the Ministry of Health’s Reference Drug Program (RDP). In anticipation of this expansion, the BPC conducted an online poll, which found a resounding 82% of British Columbians are concerned that administrators of the BC PharmaCare program will be implementing a policy that tells physicians which medications they can prescribe for patients, even if it goes against physicians’ opinions of the best care for their patients. Continue reading

Let BC PharmaCare hear “Your Voice” on apremilast

Stickman with megaphone calling for patient inputBC PharmaCare is looking for your input on apremilast for the treatment of psoriatic arthritis

Apremilast is an oral, small-molecule compound, taken as one tablet twice a day. The medication works by inhibiting the action of phosphodiesterase-4 (PDE4), an enzyme found in immune cells. The drug is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about apremilast for the treatment of psoriatic arthritis (PsA).  Continue reading

Let BC PharmaCare hear “Your Voice” on denosumab (Prolia®) for osteoporosis in men

Cartoon man with arrowBC PharmaCare is looking for your input on denosumab (Prolia®) for the treatment of osteoporosis in men

Denosumab (Prolia®) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide direct feedback about denosumab for the treatment of osteoporosis in men.

You can give input if you are a male B.C. resident living with osteoporosis, a caregiver to someone with osteoporosis, or if your group represents people who live with osteoporosis.

The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process.

It is an opportunity for you to share your perspectives on medication decisions that affect you or someone you provide care for.

Please click here to let BC PharmaCare hear Your Voice. Or, go to the following links: Continue reading

Let BC PharmaCare hear “Your Voice” on apremilast for plaque psoriasis

Cartoon man with arrowLet BC PharmaCare hear “Your Voice” on apremilast for plaque psoriasis 

BC PharmaCare is looking for your input on apremilast for the treatment of moderate to severe plaque psoriasis 

Taken orally, apremilast (Otezla®) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about apremilast for the treatment of moderate to severe plaque psoriasis.

You can give input if you are a B.C. resident and have plaque psoriasis (with or without psoriatic arthritis), a caregiver to someone with plaque psoriasis, or if your group represents people who live with plaque psorisais.  Continue reading

Let BC PharmaCare hear “Your Voice” on tofacitinib

Stickman with megaphone calling for patient inputLet BC PharmaCare hear “Your Voice” on tofacitinib for rheumatoid arthritis

Taken orally, tofacitinib (Xeljanz®) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about tofacitinib for the treatment of rheumatoid arthritis (RA).

You can give input if you are a B.C. resident and have RA, a caregiver to someone with RA, or if your group represents people who live with RA.

The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process.

It is an opportunity for you to share your perspectives on medication decisions that affect you or someone you provide care for. Continue reading